Reschke, R.; Gussek, P.; Boldt, A.; Sack, U.; Köhl, U.; Lordick, F.; Gora, T.; Kreuz, M.; Reiche, K.; Simon, J.-C.;
et al. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. Int. J. Mol. Sci. 2021, 22, 8017.
https://doi.org/10.3390/ijms22158017
AMA Style
Reschke R, Gussek P, Boldt A, Sack U, Köhl U, Lordick F, Gora T, Kreuz M, Reiche K, Simon J-C,
et al. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. International Journal of Molecular Sciences. 2021; 22(15):8017.
https://doi.org/10.3390/ijms22158017
Chicago/Turabian Style
Reschke, Robin, Philipp Gussek, Andreas Boldt, Ulrich Sack, Ulrike Köhl, Florian Lordick, Thomas Gora, Markus Kreuz, Kristin Reiche, Jan-Christoph Simon,
and et al. 2021. "Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy" International Journal of Molecular Sciences 22, no. 15: 8017.
https://doi.org/10.3390/ijms22158017
APA Style
Reschke, R., Gussek, P., Boldt, A., Sack, U., Köhl, U., Lordick, F., Gora, T., Kreuz, M., Reiche, K., Simon, J. -C., Ziemer, M., & Kunz, M.
(2021). Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. International Journal of Molecular Sciences, 22(15), 8017.
https://doi.org/10.3390/ijms22158017